NANJING, China, Jan. 30, 2026 /PRNewswire/ — On January 30, Xinhua News Agency Jiangsu Branch released the think tank report The Jiangsu Practice of Humanomics at the Release Conference on Research Outcomes of Humanomics held in Nanjing, Jiangsu Province. Comprising approximately 33,000 words across five sections, the report offers a systematic exploration of Jiangsu’s distinctive […]
Category Archives: Pr Newswire
HO CHI MINH CITY, Vietnam, Jan. 30, 2026 /PRNewswire/ — Castrol, a global leader in lubricants, launched the Castrol Superbike Fest APAC 2026 on January 28th – kicking off a region-wide premium superbike movement designed to connect Asia-Pacific’s most passionate superbike riders, specialist workshops and high-performance products, on one unified platform. More than a festival, the Castrol […]
Strategic location in Japan leverages local engineering excellence to serve global markets. OSAKA, Japan, Jan. 30, 2026 /PRNewswire/ — SuperX AI Technology Limited (NASDAQ: SUPX) (“the Company” or “SuperX”), an emerging AI Data Center infrastructure solutions provider, today announced the official start of production at its newly established SuperX Global Supply Center in Japan. Located in Tsu City, […]
LISHUI, China, Jan. 30, 2026 /PRNewswire/ — Tantech Holdings Ltd. (Nasdaq: TANH) (“Tantech” or the “Company”), today announced that its U.S. subsidiary, Tanhome Group Inc., has received a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) related to its application of the trademark “TANHOME” (Serial No. 99204946), marking a key […]
VILNIUS, Lithuania, Jan. 30, 2026 /PRNewswire/ — BTCC, the world’s longest-serving cryptocurrency exchange, announced that its tokenized precious metals futures pairs reached an all-time high of $301.7 million in daily volume on January 27, 2026, as traders sought exposure to traditional safe-haven assets amid heightened global market volatility. BTCC Hits $301M in Tokenized Precious Metals […]
Pr Newswire
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
30
Jan
Jan
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of the end of January 2026, 12 sites in the US are activated and 100 patients have been […]
30
Jan
Jan
GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of […]
Pr Newswire
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
30
Jan
Jan
mRNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolio Collaboration combines Moderna’s expertise in mRNA technology for rare metabolic disorders with Recordati’s established global rare disease commercial infrastructure Moderna will continue to lead development for mRNA-3927, and if approved, Recordati will lead global commercialization efforts Milan, 29 January 2026 – Recordati today announced […]
30
Jan
Jan
THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to […]
Pr Newswire
CareMed Has Been Selected as a National Specialty Pharmacy Provider for Exdensur (depemokimab-ulaa)
30
Jan
Jan
NEW HYDE PARK, N.Y., Jan. 29, 2026 (GLOBE NEWSWIRE) — CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by GSK for Exdensur (depemokimab), indicated for the add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.1 “We are excited to […]